Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
State:  North Carolina
Country:  U.S.A.
Results 1-25 of 39 for your search:
Start Over
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
Status: Active
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: MIP-1404-3301, NCI-2016-00399, NCT02615067
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 9785-CL-0335, NCI-2016-00640, 2015-003869-28, NCT02677896
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INO-VT-464-CL-001, NCI-2014-00229, NCT02012920
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GS-US-350-1604, NCI-2016-00521, 2015-003741-26, NCT02607228
Low-Carbohydrate Diet in Preventing Insulin Resistance and Weight Gain in Patients with Prostate Cancer Planning to Undergo Hormone Therapy
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: Pro00010519, NCI-2013-01874, NCT00932672
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Carbohydrate-Restricted Diet in Treating Patients with Previously Treated Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 20 and over
Trial IDs: Pro00041857, NCI-2013-00581, 00041857, NCT01763944
Androgen Deprivation Therapy, Enzalutamide, and Radiation Therapy in Treating Patients with Recurrent Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00049865, NCI-2014-01161, DUMC Pro00049865, NCT02057939
Abiraterone Acetate with or without Cabazitaxel in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-046, NCI-2014-01894, c12-108, NCT02218606
Exercise Training in Improving Quality of Life in Patients with Hormone Naïve Prostate Cancer Receiving Enzalutamide and Androgen Deprivation Therapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00053924, NCI-2014-02541, NCT02256111
Radium Ra 223 Dichloride in Reducing Pain in Patients with Symptomatic Metastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-098, NCI-2014-02542, c13-124, NCT02278055
Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INO-VT-464-CL-003, NCI-2015-01076, NCT02445976
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
Immune Activation in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Sipuleucel-T Immunotherapy
Status: Active
Phase: Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: Pro00047231, NCI-2015-02074, NCT02036918
Dose-escalation Study of BAY1129980
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16044, NCI-2014-01218, NCT02134197
Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
Status: Active
Phase: Phase I
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NRG-BR001, NCI-2014-00702, NCT02206334
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B7791001, NCI-2016-00393, PRCA VBIR FIP STUDY, NCT02616185
Start Over